NEWTON, Mass. A company that develops carbohydrate-based drugs to treat cancer and fibrosis has made a new executive appointment.
Pro-Pharmaceuticals announced Monday the appointment of Prism Technologies founder Arthur Greenberg to its board of directors.
“We are very pleased to have Mr. Greenberg join our board of directors,” Pro-Pharmaceuticals CEO Theodore Zucconi said in a statement. “Bobby is a highly regarded executive with a wealth of business experience.”
The company is planning to commercialize one of its products, Davanat, a colorectal and biliary cancer treatment.